Jazz Pharmaceuticals plc SC TO-T/A, filed Mar 28, 2025
Jazz Pharmaceuticals plc (JAZZ)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE TO/A
Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1)
of the Securities Exchange Act of 1934
(Amendment No. 1)
CHIMERIX, INC.
(Name of Subject Company)
PINETREE ACQUISITION SUB, INC.
(Offeror)
JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
(Parent of Offeror)
(Names of Filing Persons)
Common stock, par value $0.001 per share
(Title of Class of Securities)
16934W106
(CUSIP Number of Class of Securities)
Neena M. Patil
Jazz Pharmaceuticals Public Limited Company
Executive Vice President and Chief Legal Officer
Fifth Floor, Waterloo Exchange
Waterloo Road, Dublin 4, Ireland D04 E5W7
011-353-1-634-7800
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Persons)
With a copy to:
Mark Gordon, Esq.
Victor Goldfeld, Esq.
Wachtell, Lipton, Rosen & Katz
51 West 52nd Street
New York, NY 10019
(212) 403-1000
| ☐ | Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
Check the appropriate boxes below to designate any transactions to which the statement relates:
| ☒ | third-party tender offer subject to Rule 14d-1. |
| ☐ | issuer tender offer subject to Rule 13e-4. |
| ☐ | going-private transaction subject to Rule 13e-3. |
| ☐ | amendment to Schedule 13D under Rule 13d-2. |
Check the following box if the filing is a final amendment reporting the results of the tender offer: ☐
If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:
| ☐ | Rule 13e-4(i) (Cross-Border Issuer Tender Offer) |
| ☐ | Rule 14d-1(d) (Cross-Border Third-Party Tender Offer) |
This Amendment No. 1 (this “Amendment”) amends and supplements the Tender Offer Statement on Schedule TO filed by Pinetree Acquisition Sub, Inc., a Delaware corporation (“Purchaser”) and an indirect wholly owned subsidiary of Jazz Pharmaceuticals Public Limited Company, an Irish public limited company (“Jazz”), with the U.S. Securities and Exchange Commission on March 21, 2025 (together with any subsequent amendments and supplements thereto, the “Schedule TO”). The Schedule TO relates to the offer by Purchaser to purchase all of the outstanding shares of common stock, par value $0.001 per share (the “Shares”), of Chimerix, Inc., a Delaware corporation (“Chimerix”), in exchange for $8.55 per Share, payable in cash without interest and subject to reduction for any applicable withholding taxes, upon the terms and conditions set forth in the offer to purchase, dated March 21, 2025 (the “Offer to Purchase”), a copy of which is attached as Exhibit (a)(1)(A), and in the related letter of transmittal (the “Letter of Transmittal”), a copy of which is attached as Exhibit (a)(1)(B), which, as each may be amended or supplemented from time to time, collectively constitute the “Offer.”
Except as otherwise set forth in this Amendment, the information set forth in the Schedule TO remains unchanged and is incorporated herein by reference to the extent relevant to the items in this Amendment. Capitalized terms used but not defined herein have the meanings ascribed to them in the Schedule TO.
| Item 12. | Exhibits. |
Item 12 of the Schedule TO is hereby amended and supplemented by adding the following exhibit:
| Exhibit No. |
Description | |
| (a)(1)(I) | Employee Communication from March 28, 2025 | |
SIGNATURES
After due inquiry and to the best of their knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.
Dated: March 28, 2025
| PINETREE ACQUISITION SUB, INC. | ||
| By: | /s/ Alan Campion | |
| Name: | Alan Campion | |
| Title: | Vice President, Finance | |
| JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY | ||
| By: | /s/ Philip L. Johnson | |
| Name: | Philip L. Johnson | |
| Title: | Executive Vice President & | |
| Chief Financial Officer | ||
- 2 -
Exhibit (a)(1)(I)
| A Message from Jazz’s Chief People Officer |
| |
| Heidi Manna | ||
| Executive Vice President and Chief People Officer |
Dear Chimerix Team,
It’s been a few weeks since the announcement of our transaction and outreach through the short welcome video from CEO Bruce Cozadd and the Jazz Global Leadership team. I can assure you that although the airwaves have been a little bit quiet, our excitement to meet you and enthusiasm for what we can accomplish together has only grown.
At Jazz, we know that you have worked hard and built a special company with enormous potential to change the lives of patients and their families. We’re so excited to bring on a team that has experience with dordaviprone and the expertise to progress this important pipeline asset to potential FDA approval and commercialization.
Until the close of our transaction, Jazz and Chimerix will operate as independent companies and continue to focus on our responsibilities to our people, patients and customers. In the weeks ahead, we hope to get to know each and every one of you and learn more about your contributions to the Chimerix success story.
Thanks to a generous invitation from Michael Andriole and Mark Bernatz we’re going to have a near-term opportunity. In the weeks ahead, you will receive an outlook invitation to meet a small Jazz delegation in-person on April 15, 2025 in your offices at 2505 Meridian Pkwy, Suite 100, Durham, NC 27713. Although I won’t be able to attend due to a previous travel commitment, our delegation will include executive management from Jazz R&D, Human Resources and the Integration Team. During this informal meeting they will share what we can about our next steps, take time to listen to what’s on your mind, and answer all of the questions they can. Look out for more details on that meeting soon.
As we look forward to this exciting connection date and learning more about you, your Chimerix HR colleagues have told me that you might like to know a bit more about Jazz. This will be the first in a short series of messages we will send your way.
I appreciate that by now you’ve seen our company homepage and unearthed a few basics, so I thought I’d go a bit beyond headlines and share more with you about Our Jazz People & Culture.
We’re looking forward to seeing you on April 15, 2025.
Our Jazz People and Culture Click to learn more [Graphic Appears Here] azz marketed is a fully medicines integrated, and novel global product biopharmaceutical candidates for adults company and with children, a diverse and expertise portfolio of in wo key therapeutic areas: neuroscience and oncology. Our expertise Jazz. Executive Jazz has ~2800 Committee employees, has nine affectionately members known ; each with as Jazzicians an important . Together, area of we are backgrounds experts, analysts, and perspectives specialists, . At advocates, Jazz we believe scientists, that inclusion and professionals and belonging all with are diverse key to unlocking organization, business and truly value living and our the values potential . of our people, building a high-performance [Graphic Appears Here] Working market. Jazz together, medicines we are are proud available to support in nearly patients, 100 innovate countries and , and bring our new global medicines to commercial o patients. footprint and operations allow us to rapidly advance our medicines and deliver[Graphic Appears Here] greater Jazzicians level work of flexibility flexibly in to a how work and model where we work call gets Jazz done, Remix helping . It’s designed teams pioneer to provide a solutions to transform the lives of patients. [Graphic Appears Here] We o transform share your the passion lives of for patients innovation and their and families for developing . Since medicines the day Jazz that was have founded the potential in 2003 diseases , we — have often focused with limited on developing or no treatment life-changing options medicines—so they for can people live their with lives serious more ully. [Graphic Appears Here] Everything performance, we and do at being Jazz a is great focused place on to three work things: through putting living patients our shared first, values driving -- high-ntegrity, innovation, pursuit of excellence, passion and collaboration. Your eedback Voice through Matters a at continuous Jazz, so we’ve listening created approach more . The opportunities goal of continuous for Jazzicians listening to share is to allows check in us with to act Jazzicians with more on agility an ongoing and work basis together throughout to make the changes year. Real that -time improve feedback the work experience at Jazz. At wellbeing Jazz we is believe an important that caring factor for in patients our high begins -performance with caring journey for .our In 2025, people we . Employee made some wellbeing mportant investments -- mind, body, in finances wellbeing and . We work launched -life. By Note placing to Self, all resources a single brand under for one all umbrella, things we each made optimal it easier wellbeing to find . In and addition, understand we will the hold tools a Jazz and resources Wellbeing Jazz Week provides in 2025, to providing help folks dedicated time off to all Jazz employees to focus on wellbeing and self-care. address Through unmet dedicated needs, volunteer promote work equity, and commitment and help people to social lead healthier, impact, Jazzicans more fulfilling strive lives to . Community ostering meaningful engagement connections is a fundamental with the communities aspect of our we mission serve. is We crucial recognize for Our Jazz People and Culture
Forward-Looking Statements
This communication contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Jazz
Pharmaceuticals Public Limited Company, an Irish public limited company plc (“Parent”) and Chimerix, Inc., a Delaware corporation (“Chimerix”), including statements regarding Parent’s proposed acquisition of Chimerix, the
anticipated occurrence, manner and timing of the proposed tender offer, the closing of the proposed acquisition and the prospective benefits of the proposed acquisition, including benefits from dordaviprone’s potential to improve the standard
of care for a rare oncology disease and also contribute durable revenue beginning in the near-term; dordaviprone’s potential to rapidly become a standard of care and a meaningful therapy for patients with limited treatment options; the
potential for a near-term commercial launch of dordaviprone in the U.S. if approved; the potential of the ongoing Phase 3 ACTION trial to confirm clinical benefit of dordaviprone in recurrent H3 K27M-mutant diffuse glioma and extend its use in
first-line patients; dordaviprone potentially being eligible for a Rare Pediatric Disease PRV; Parent’s anticipated source of funds for the proposed acquisition; and other statements that are not historical facts. Actual results could differ
materially from those anticipated in these forward-looking statements. Except as required by law, each of Parent and Chimerix assume no obligation to update these forward-looking statements, whether as a result of new information, future events or
otherwise. These statements, which represent each of Parent’s and Chimerix’s current expectations or beliefs concerning various future events that are subject to significant risks and uncertainties, may contain words such as
“may,” “will,” “would,” “could,” “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “project,” “seek,”
“should,” “strategy,” “future,” “opportunity,” “potential” or other similar words and expressions indicating future results. Risks that may cause these forward-looking statements to be inaccurate
include, without limitation: uncertainties as to how many of Chimerix’s stockholders will tender their stock in the offer; the possibility that competing offers will be made; the possibility that various closing conditions for the transaction
may not be satisfied or waived, including that a governmental entity may prohibit, delay, or refuse to grant approval for the consummation of the transaction (or only grant approval subject to adverse conditions or limitations); the difficulty of
predicting the timing or outcome of regulatory approvals or actions, if any; the possibility that the transaction does not close; risks related to the parties’ ability to realize the anticipated benefits of the proposed acquisition, including
the possibility that the expected benefits from the proposed acquisition will not be realized or will not be realized within the expected time period and that Parent and Chimerix will not be integrated successfully or that such integration may be
more difficult, time-consuming or costly than expected; the risk that competing offers or acquisition proposals will be made; the effects of the transaction on relationships with employees, customers, suppliers, other business partners or
governmental entities; negative effects of this announcement or the consummation of the proposed acquisition on the market price of Parent’s ordinary shares or Chimerix’s common stock and/or Parent’s or Chimerix’s operating
results; significant transaction costs; unknown or inestimable liabilities; the risk of litigation and/or regulatory actions related to the proposed acquisition; Parent’s ability to fund the acquisition with existing cash and investments;
effectively launching and commercializing products and product candidates such as dordaviprone, if approved; the successful completion of development and regulatory activities with respect to dordaviprone; obtaining and maintaining adequate coverage
and reimbursement for Parent’s or Chimerix’s products; the time-consuming and uncertain regulatory approval process, including the risk that Chimerix’s NDA for dordaviprone seeking accelerated approval for treatment of H3 K27M-mutant
diffuse glioma in adult and pediatric patients with progressive disease following prior therapy may not be approved by FDA in a timely manner or at all, and that Chimerix and/or Parent may not receive a Rare Pediatric Disease PRV upon potential
approval of dordaviprone; the costly and time-consuming pharmaceutical product development and the uncertainty of clinical success, including risks related to failure or delays in successfully initiating or completing clinical trials and assessing
patients, including with respect to current and planned future clinical trials of dordaviprone; global economic, financial, and healthcare system disruptions and the current and potential future negative impacts to Parent’s or Chimerix’s
business operations and financial results; the sufficiency of Parent’s or Chimerix’s cash flows and capital resources; Parent’s or Chimerix’s ability to achieve targeted or expected future financial performance and results and
the uncertainty of future tax, accounting and other provisions and estimates; and other risks and uncertainties affecting Parent and Chimerix, including those described from time to time under the caption “Risk Factors” and elsewhere in
their respective filings and reports with the SEC, including Parent’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and Chimerix’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 as well as the Tender Offer Statement on Schedule TO and related tender offer documents filed by Parent and Pinetree Acquisition Sub, Inc., a Delaware
corporation and wholly owned indirect subsidiary of Parent (“Purchaser”) on March 21, 2025, and the Solicitation/
Recommendation Statement on Schedule 14D-9 filed by Chimerix on
March 21, 2025. Any forward-looking statements are made based on the current beliefs and judgments of Parent’s and Chimerix’s management, and the reader is cautioned not to rely on any forward-looking statements made by Parent or
Chimerix. Except as required by law, Parent and Chimerix do not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new
information, future events, or otherwise.
Additional Information and Where to Find It
This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares of Chimerix. Parent and Purchaser have filed a tender offer statement on Schedule TO with the SEC, containing an Offer to Purchase all of the outstanding shares of common stock of Chimerix, and Chimerix has filed a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. CHIMERIX’S STOCKHOLDERS AND OTHER INVESTORS ARE URGED TO READ CAREFULLY THE TENDER OFFER MATERIALS (INCLUDING THE OFFER TO PURCHASE, THE RELATED LETTER OF TRANSMITTAL AND OTHER TENDER OFFER DOCUMENTS), AS WELL AS THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 BECAUSE THEY EACH CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF CHIMERIX SECURITIES AND OTHER INVESTORS SHOULD CONSIDER BEFORE MAKING ANY DECISION WITH RESPECT TO THE TENDER OFFER. The Offer to Purchase, the related Letter of Transmittal and other tender offer documents, as well as the Solicitation/Recommendation Statement on Schedule 14D-9, have been sent to all stockholders of Chimerix at no expense to them and are available for free at the SEC’s website at www.sec.gov. Additional copies may be obtained for free by contacting either Parent or Chimerix. Copies of the documents filed with the SEC by Chimerix are available free of charge on Chimerix’s website at https://www.chimerix.com or by contacting Chimerix at IR@chimerix.com. Copies of the documents filed with the SEC by Parent are available free of charge on Parent’s website at https://investor.jazzpharma.com or by contacting Parent’s Investor Relations Department at investorinfo@jazzpharma.com.
In addition to the Offer to Purchase, the related Letter of Transmittal and other tender offer documents, as well as the Solicitation/Recommendation Statement on Schedule 14D-9, Parent and Chimerix each file annual, quarterly and current reports, proxy statements and other information with the SEC, which are available to the public over the internet at the SEC’s website at http://www.sec.gov.